about
Antidepressants versus placebo for depression in primary carePharmaceutical interventions for emotionalism after strokeAn intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?Post-stroke Mood and Emotional Disturbances: Pharmacological Therapy Based on MechanismsPathological laughter and crying in patients with closed traumatic brain injuryFluoxetine as a treatment for post-stroke emotionalismPathological laughing and cryingAmyotrophic lateral sclerosis and palliative care: where we are, and the road ahead.Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.Depression and dementia: comorbidities, identification, and treatment.Citalopram in the treatment of depression and other potential uses in psychiatry.Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affectPseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.Depressive syndromes in dementia.Citalopram: a comprehensive review.Pseudobulbar affect: an under-recognized and under-treated neurological disorder.Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 2: Treatment alternatives.Abnormal pontine activation in pathological laughing as shown by functional magnetic resonance imaging.Treatment of neuropsychiatric conditions associated with multiple sclerosis.Treatment of psychiatric syndromes due to cerebrovascular disease.Preventing depression after stroke.Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group.Dextromethorphan/quinidine sulfate for pseudobulbar affect.Psychiatric comorbidity and quality of life in patients with post-stroke emotional incontinenceCurrent concepts in the pharmacotherapy of pseudobulbar affect.Crying and suicidal, but not depressed. Pseudobulbar affect in multiple sclerosis successfully treated with valproic acid: Case report and literature review.Neuronal Dysregulation in Stroke-Associated Pseudobulbar Affect (PBA): Diagnostic Scales and Current Treatment OptionsIn thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner.Serotonin 5HT1A receptor availability and pathological crying after stroke.Synthesis and Antimicrobial Screening of Novel 4-Substituted Phenyl-5-[1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl]-2H-1,2,4-triazole-3-thiones.EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives.Management of post-stroke mood and emotional disturbances.Associations of serotonergic genes with poststroke emotional incontinence.Successful treatment of poststroke emotional incontinence with yokukansan, an Asian herbal medicine: report of two cases.Emotional incontinence: a dramatic response to paroxetine.Memantine may affect pseudobulbar affect in patients with Alzheimer's disease.Post-Stroke depression and pathological crying: Clinical aspects and new pharmacological approaches
P2860
Q24239979-8872E58F-0DC7-4319-B561-7FF0F7AA9FD4Q24240045-E9028CC0-08C4-4E38-B03F-2DA11F60B3A4Q27491346-D9E36687-D6F3-45BF-9D31-4CD0FFC3BA03Q28073424-635BD39D-26CE-4713-8AB4-596087631ED9Q28291902-CA92FB51-1C4B-44CF-AF0F-CA095947A56CQ28293082-8ECEA0DF-F254-454E-8A39-2A232F2555BEQ28294521-E5A1B033-0907-4224-BC01-E0B809DD61CCQ30455100-6749C61A-8544-48B7-83C6-B7D7EFEE1921Q30634431-E2B40980-0EF7-43ED-AE18-05CB01A70060Q33609585-C087F00D-C5C7-4CAB-8CC0-9966631C1069Q33677537-BB144097-52D7-4541-A9C4-AE73BF151419Q33838839-7BE3876F-54D4-4647-A94D-A7E65B35A3DBQ34026748-7247BC5B-18BC-4F0F-8971-470F0C4DC4F6Q34174245-E3AD75F4-D3A3-4053-8A21-35E18B7B66F9Q34240991-893AD299-F06D-4F60-A6D9-102438643A00Q34630034-D3163251-8C64-40AD-A2D7-D995DA9A2121Q34643816-6DA05D1B-9CD3-46E5-8AE6-72750B7C19E6Q36142020-E79B376E-35B8-4F6A-95FE-6BD052763326Q36641533-C387BFAC-AB2A-4634-B55C-8D277250A7CAQ36645263-852D3DD1-506D-4E64-B3CD-FF4E26FD78CFQ36645268-B9F3E0B0-BF49-4F1C-A890-DAB7CD8A08E9Q36892306-E5CCF302-65A1-4FBA-8E65-2212E95D9150Q37366440-50857360-7202-42D9-8D9B-16B9CEC9EA58Q37516072-DF70DC83-B630-44DD-B374-54BB74D15E20Q37895256-FE7DC38B-E6A9-4E32-9788-5D0914EB2178Q38219309-179C93D8-DFB3-4275-80A7-EBE33CC3242EQ38676032-499D7B68-1214-4828-9AFA-B7B5B15F1497Q41844874-92145F38-8127-49C9-A655-777DBAA0816FQ42516638-D3F6E126-3678-4A51-BA4B-FFE07E79F319Q42605137-1650F7EC-C91F-4C1B-834A-10B7C0F6586FQ46832663-4B09B5C8-C846-4CBE-A601-C9126C1BF35EQ47731936-0AF441E7-1B6C-4ECE-872D-02145A508C28Q48900895-4A224C36-7F2A-4295-B791-66B03388313FQ50590298-887DBC19-7FEA-4F86-9FCC-5CFA23B9C085Q51108721-165B3746-2614-4213-8EC3-55DA2FC2A1E0Q54262422-99A2172F-519D-47A6-BFC3-5A7D8A68DF6AQ58260124-DD769539-DC46-4BCF-8C17-C83DACA8D43F
P2860
description
1993 nî lūn-bûn
@nan
1993 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Citalopram for post-stroke pathological crying
@ast
Citalopram for post-stroke pathological crying
@en
Citalopram for post-stroke pathological crying
@nl
type
label
Citalopram for post-stroke pathological crying
@ast
Citalopram for post-stroke pathological crying
@en
Citalopram for post-stroke pathological crying
@nl
prefLabel
Citalopram for post-stroke pathological crying
@ast
Citalopram for post-stroke pathological crying
@en
Citalopram for post-stroke pathological crying
@nl
P2093
P3181
P1433
P1476
Citalopram for post-stroke pathological crying
@en
P2093
G Andersen
K Vestergaard
P3181
P356
10.1016/0140-6736(93)92696-Q
P407
P577
1993-10-02T00:00:00Z